Sleep-wake disorders:

Indications for INTERMEZZO:

As needed use for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Not indicated for treatment of middle-of-the-night insomnia when patient has <4 hours of bedtime remaining before planned time of waking.


Place 1 tab under the tongue and allow to disintegrate completely before swallowing. ≥18yrs: 1.75mg (women) or 3.5mg (men) (take only once per night if needed and only if at least 4 hours of bedtime remain before the planned time of waking). Concomitant CNS depressants, elderly (≥65yrs), hepatic impairment: 1.75mg (men and women). Effect delayed if taken with or immediately after a meal.


<18yrs: not recommended.


Risk of CNS depressant effects and next-day impairment. Evaluate for co-morbid diagnoses (eg, physical and/or psychiatric disorders) prior to treatment. Reevaluate if insomnia fails to remit after 7–10 days of use. Depression. Suicidal tendencies. Abnormal thinking and behavioral changes. Compromised respiratory function. Sleep apnea. Myasthenia gravis. Hepatic impairment. Drug or alcohol abusers. Write ℞ for smallest practical amount. Elderly (higher risk of falls). Pregnancy (Cat.C). Nursing mothers.

Pharmacologic Class:

Imidazopyridine hypnotic.


Additive effects with concomitant other CNS depressants (eg, benzodiazepines, opioids, tricyclic antidepressants, imipramine, chlorpromazine or alcohol); reduce dose. Concomitant with other sedative-hypnotics including other zolpidem products: not recommended. Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole). Reduced exposure by CYP3A4 inducers (eg, rifampin).

Adverse Reactions:

Headache, nausea, fatigue; CNS effects, complex behaviors (eg, sleep-driving), anaphylaxis, angioedema, withdrawal effects, others (see full labeling).

Generic Availability:


How Supplied:

Sublingual tabs—30

Pricing for INTERMEZZO

3.5mg sublingual (Qty: 30)
Appx. price $95